AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug
Written by
BioPharma Dive
Published
0
comments
0
min
The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.